Is Vaginal Misoprostol Better Than Dinoprostone for IOL?
Induction of labour is one of the most frequent obstetric interventions worldwide. Choosing the optimal cervical ripening agent remains critical for successful delivery. A comprehensive systematic review evaluates the efficacy of vaginal misoprostol induction compared to vaginal dinoprostone in singleton term pregnancies. Therefore, understanding these comparative outcomes helps clinicians optimize intrapartum care protocols.
The meta-analysis evaluated 44 randomized controlled trials comprising 13,644 pregnant individuals. Specifically, 7,040 participants received vaginal misoprostol, whereas 6,604 participants received vaginal dinoprostone. The primary outcome focused on achieving vaginal delivery within 24 hours of induction initiation.
Evidence on Vaginal Misoprostol Induction Outcomes
The findings demonstrate clear benefits regarding delivery timelines. Participants receiving vaginal misoprostol achieved a 48% higher rate of vaginal delivery within 24 hours (OR 1.48, 95% CI 1.20 to 1.84). Furthermore, misoprostol significantly reduced the overall induction-to-birth interval by approximately 230 minutes.
Additionally, clinicians observed a substantial reduction in oxytocin augmentation among women receiving misoprostol (OR 0.51, 95% CI 0.40 to 0.65). Consequently, misoprostol facilitates faster labour progression without requiring frequent supplemental oxytocin infusions.
Maternal and Neonatal Safety Profiles
Reassuringly, the review demonstrated comparable overall safety outcomes between the two prostaglandin agents. Cesarean delivery rates showed no statistically significant difference between the cohorts. Moreover, the incidences of adverse maternal events and neonatal intensive care admissions remained equivalent.
However, dosage selection plays a pivotal role in minimizing hyperstimulation risks. The subgroup analysis showed that a 25 microgram dose maintained efficacy while reducing uterine hyperstimulation with fetal heart rate changes. In contrast, higher doses equal to or exceeding 50 micrograms increased hyperstimulation rates.
Clinical Implications for Practice
These findings provide actionable insights for obstetric decision-making. Vaginal misoprostol offers superior efficiency and reduces the need for oxytocin augmentation. Therefore, adopting a 25 microgram dosing regimen balances rapid delivery success with fetal safety. In addition, misoprostol provides substantial cost advantages and room-temperature stability compared to temperature-sensitive dinoprostone formulations.
For practitioners looking to expand their expertise in managing labor and delivery, structured training programs offer invaluable evidence-based updates.
Frequently Asked Questions
Q1: Is vaginal misoprostol more effective than dinoprostone for labor induction?
Yes, meta-analytic evidence confirms that vaginal misoprostol increases 24-hour vaginal delivery rates by 48% and shortens delivery time by nearly four hours.
Q2: What misoprostol dose is recommended to reduce uterine hyperstimulation?
A low starting dose of 25 micrograms vaginally provides high clinical efficacy. Furthermore, this dose significantly reduces uterine hyperstimulation risks compared to regimens of 50 micrograms or higher.
References
- Andersson G et al. Vaginal Misoprostol Compared to Vaginal Dinoprostone for Induction of Labour: A Systematic Review and Meta-Analysis. BJOG. 2026 Aug 19. doi: 10.1111/1471-0528.70314. PMID: 42615117.
- Kerr R, et al. Low-dose oral misoprostol for induction of labour. Cochrane Database Syst Rev. 2021;6(6):CD014484.
- World Health Organization. WHO recommendations for induction of labour. Geneva: World Health Organization; 2018.
